Carbapenem-Resistant
antibiotic consumption
carbapenem-resistant Pseudomonas aeruginosa bacteremia
hospital
infection control interventions
Journal
Microorganisms
ISSN: 2076-2607
Titre abrégé: Microorganisms
Pays: Switzerland
ID NLM: 101625893
Informations de publication
Date de publication:
17 May 2023
17 May 2023
Historique:
received:
26
04
2023
revised:
14
05
2023
accepted:
15
05
2023
medline:
15
6
2023
pubmed:
15
6
2023
entrez:
15
6
2023
Statut:
epublish
Résumé
Carbapenem-resistant We prospectively recorded the incidence of CRPA bacteremia, antibiotic consumption, use of hand-hygiene solutions, and isolation rates of multidrug-resistant (MDR) carrier patients. The consumption of colistin, aminoglycosides, and third-generation cephalosporins decreased significantly in the total hospital and its divisions ( In our hospital, multimodal infection control interventions resulted in a significant reduction of CRPA bacteremia, mostly due to the reduction of all classes of antibiotics.
Sections du résumé
BACKGROUND
BACKGROUND
Carbapenem-resistant
METHODS
METHODS
We prospectively recorded the incidence of CRPA bacteremia, antibiotic consumption, use of hand-hygiene solutions, and isolation rates of multidrug-resistant (MDR) carrier patients.
FINDINGS
RESULTS
The consumption of colistin, aminoglycosides, and third-generation cephalosporins decreased significantly in the total hospital and its divisions (
CONCLUSION
CONCLUSIONS
In our hospital, multimodal infection control interventions resulted in a significant reduction of CRPA bacteremia, mostly due to the reduction of all classes of antibiotics.
Identifiants
pubmed: 37317288
pii: microorganisms11051315
doi: 10.3390/microorganisms11051315
pmc: PMC10220838
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
JAMA Netw Open. 2023 Feb 1;6(2):e2253806
pubmed: 36757700
J Mol Biol. 2015 Nov 20;427(23):3628-45
pubmed: 26319792
J Hosp Infect. 2022 May;123:27-33
pubmed: 35149172
Adv Ther. 2017 Apr;34(4):854-865
pubmed: 28303388
Adv Exp Med Biol. 2022;1386:117-143
pubmed: 36258071
Biotechnol Adv. 2019 Jan - Feb;37(1):177-192
pubmed: 30500353
Curr Opin Pharmacol. 2007 Jun;7(3):244-51
pubmed: 17418640
BMJ. 1998 Apr 18;316(7139):1236-8
pubmed: 9553006
Clin Microbiol Infect. 2019 May;25(5):555-561
pubmed: 30472426
Int J Mol Sci. 2021 Mar 18;22(6):
pubmed: 33803907
J Glob Antimicrob Resist. 2020 Dec;23:430-438
pubmed: 33176216
Expert Rev Anti Infect Ther. 2018 Feb;16(2):89-110
pubmed: 29310479
Drugs. 2021 Dec;81(18):2117-2131
pubmed: 34743315
Microb Drug Resist. 2022 Jul;28(7):806-818
pubmed: 35834622
Int J Infect Dis. 2019 Jul;84:153-162
pubmed: 31204003
Crit Care Res Pract. 2011;2011:416426
pubmed: 21687626
Clin Infect Dis. 2019 Nov 13;69(Suppl 7):S521-S528
pubmed: 31724045
PLoS One. 2022 Jan 14;17(1):e0261917
pubmed: 35030191
Pathogens. 2014 Apr 10;3(2):309-40
pubmed: 25437802
Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0200021
pubmed: 34807753
Am J Infect Control. 2019 Aug;47(8):1035-1037
pubmed: 30732979
Infect Control Hosp Epidemiol. 2019 Sep;40(9):1056-1058
pubmed: 31232265
Eur J Clin Microbiol Infect Dis. 2022 Jan;41(1):127-132
pubmed: 34264401
Front Cell Infect Microbiol. 2022 Jul 06;12:926758
pubmed: 35873152
Appl Microbiol Biotechnol. 2020 Dec;104(24):10655-10667
pubmed: 33151366
J Hosp Infect. 2018 Aug;99(4):396-404
pubmed: 29792971
Eur J Clin Microbiol Infect Dis. 2018 Jul;37(7):1211-1220
pubmed: 29644540
Antimicrob Resist Infect Control. 2020 Jan 3;9(1):3
pubmed: 31911831
Syst Rev. 2017 Dec 13;6(1):256
pubmed: 29237496
J Microbiol Immunol Infect. 2023 Apr;56(2):337-343
pubmed: 36210318